Merrie Mosedale, PhD, research assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy, was recently awarded the 2017 Sternfels Prize for Drug Safety and Innovation. Dr. Mosedale received the Prize for her scholarship and work on HLA-based mechanisms of drug-induced liver injury (DILI).
Dr. Mosedale is also the assistant director of the Institute for Drug Safety Sciences at the UNC Eshelman School of Pharmacy, where she leads the Translational Pharmacogenomics Research Program. Through partnerships with pharmaceutical companies and academic scientists, she is working to solve safety problems by integrating cutting-edge omics approaches with novel in vivo, in vitro, and in silico platforms.
Dr. Mosedale’s current research focuses on the application of mouse genetics to identify individual susceptibilities to adverse drug reactions in humans, organotypic culture models to understand mechanisms of drug toxicities, and exosome biology to predict toxicity liabilities earlier in drug development. Findings from her research highlight the potential for these novel approaches to improve human risk assessment in drug-safety testing as well as to provide mechanistic insights into drug toxicity.
Dr. Mosedale was a recipient of the 2013 ASPET Integrative Research in Pharmacology Postdoctoral Award. Dr. Mosedale has been an ASPET member since 2008 and is a member of the Divisions for Toxicology and Molecular Pharmacology.
Last updated: March 3, 2017